

SUPPLEMENTARY DATA

Table 1 of the supplementary data

Baseline characteristics of the patients included in the matched cohorts

	Matched cohort		
	PEA/BPA	Medical therapy	P
Total	290 (49.3)	296 (50.3)	-
Female sex	143 (48.6)	172 (58.5)	.010
Age, y	56 ± 16	53 ± 19	.046
Body mass index, kg/m ²	27 ± 4	28 ± 5	.447
WHO FC III-IV, n (%)	197 (52.3)	180 (47.7)	.250
6-min walk test distance, m	395 ± 128	356 ± 115	.117
NT-proBNP, ng/mL*	413 ± 1164	1178 ± 2498	.036
mPAP, mmHg	44 ± 10	49 ± 7	.108
PAPi*	8.1 ± 6	6.4 ± 3.7	.070
PVR, din/s/cm ⁵	664 ± 352	744 ± 352	.044
Cardiac index, L/min/m ²	2.4 ± 0.4	2.3 ± 0.5	.080
TAPSE < 17 mm	80 (44.4)	77 (45.3)	.479
End-diastolic right ventricular diameter, mm	38.9 ± 7.1	39.6 ± 10.5	.472
Eccentricity index	1.2 ± 0.2	1.2 ± 0.3	.119
Pericardial effusion	39 (15.1)	22 (8.8)	.020
Oral monotherapy	106 (36.1)	149 (49.3)	.001
Combined oral therapy	56 (19)	66 (22.4)	.180
Combined oral and prostanoid analogs	24 (8.2)	27 (9.2)	.770
Riociguat	82 (71.3)	79 (72.4)	.426
Dead	34 (11.6)	98 (33.3)	.001

BPA, balloon pulmonary angioplasty; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PEA, pulmonary endarterectomy; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; WHO FC, World Health Organization functional class.

Data are expressed as no. (%), mean ± standard deviation.

Table 2 of the supplementary data

Univariable Cox regression analysis adjusted within the matched cohort

	HR (95%CI)	P
6-min walk test distance at diagnosis (per 20 m)	0.90 (0.87-0.94)	< .001
Pulmonary vascular resistance at diagnosis (per 240 din/s/cm ⁵)	1.24 (1.15-1.33)	< .001
Pulmonary artery pulsatility index (per 5 U)	0.72 (0.57-0.91)	.005
Right ventricular systolic dysfunction (TAPSE < 17 mm)	2.58 (1.45-4.60)	.001
Prostacyclin therapy	2.09 (1.34-3.27)	.001
BPA/PEA treatment	0.29 (0.19-0.42)	< .001
Diagnosis date 2007-2012	1.77 (1.20-2.60)	.004
Referral to a PH expert center	0.59 (0.41-0.83)	.003

95%CI, 95% confidence interval; BPA, balloon pulmonary angioplasty; HR, hazard ratio; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; TAPSE, tricuspid annular plane systolic excursion.

Table 3 of the supplementary data

Temporal differences over the study period

	2007-2012	2013-2018	P
Total	451 (44.3)	568 (55.7)	-
Female sex	256 (56.8)	320 (56.3)	.330
Age, y	60 ± 15	62 ± 14	.003
WHO functional class III-IV	322 (71.4)	339 (59.7)	< .001
6-min walk test distance at diagnosis, m	344 ± 116	371 ± 122	.002
Pulmonary vascular resistance at diagnosis, din/s/cm^5	816 ± 480	688 ± 360	< .001
Oral monotherapy	150 (33.3)	284 (50.1)	< .001
Combined oral therapy	129 (71.4)	98 (17.3)	< .001
Combined oral and prostanoid analogs	67 (14.9)	32 (5.6)	< .001
Pulmonary endarterectomy	141 (31.3)	216 (38)	.014

WHO FC, World Health Organization functional class.

Data are expressed as No. (%) or mean ± standard deviation.

Table 4 of the supplementary data

Comparison of clinical and hemodynamic parameters between baseline and after interventional treatment

	Baseline	Post-PEA (n = 350)	P
6-min walk test distance, m	380 ± 119	455 ± 106	< .001
End-diastolic right ventricle diameter, mm	42.7 ± 9.3	37.2 ± 8.4	.003
NT-proBNP, ng/mL	[537-2420]	[218-368]	< .001
Cardiac index, L/min/m ²	2.3 ± 0.5	2.7 ± 0.6	.013
mPAP, mmHg	44 ± 10	29 ± 10	< .001
PVR, din/s/cm ⁵	752 ± 440	320 ± 208	< .001
6-min walk test distance, m	387 ± 103	441 ± 119	< .001
End-diastolic right ventricular diameter, mm	39 ± 2	35 ± 2	< .001
NT-proBNP, ng/mL	[1503-1864]	[388-704]	.001
Cardiac index, L/min/m ²	2.3 ± 0.6	2.8 ± 0.6	< .001
Mean PAP, mmHg	45 ± 11	27 ± 8	< .001
PVR, din/s/cm ⁵	712 ± 376	256 ± 96	.003

mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAP, pulmonary artery pressure; PEA, pulmonary endarterectomy; PVR, pulmonary vascular resistance.

Data are expressed as No. (%), mean ± standard deviation, or median [interquartile range].